Healthcare Investment Diligence: Test the Promise Against Delivery

Public fact: new HHS OIG reports issued June 11 and highlighted again on June 17 found that inaccurate Medicaid managed care provider directories and network lists may limit access to maternal health care and weaken state oversight. That matters because maternal access is one of the clearest places where a network can look compliant on paper while failing in the actual patient journey.

The OIG findings justify examining the gap between listed and reachable care. I would distinguish an inaccurate contact record from a provider who is correctly listed but lacks relevant availability. Data remediation and capacity investment solve different problems.

The business case should measure successful contact, appropriate availability and completed referral against the full referred population. Assign responsibility when no service can be found. A cleaner directory creates limited value if the binding constraint remains clinical capacity.

Public fact: CMS' June 18 MLN Connects newsletter elevated two governance signals at once. First, CMS is proposing a permanent framework for the Medicare Drug Price Negotiation Program, moving the effort from annual guidance into a more predictable regulatory structure. Second, CMS highlighted stronger oversight of accrediting organizations responsible for surveying more than 9,000 providers and suppliers.

A proposed permanent framework and stronger oversight expectations have different legal and operational status. I would preserve those distinctions in planning and identify the exact obligations that apply to each affected entity.

The investment implication is to budget policy interpretation, process change, evidence retention and ongoing maintenance. Greater predictability can support planning, but it does not eliminate execution cost or justify assuming that all rules and payment terms remain unchanged.

Public fact: PwC's health services midyear outlook, reported June 17, says deal volume softened while value remained resilient, with investors repricing risk rather than retreating from healthcare altogether. Physician medical groups captured a record share of first-quarter deal volume, while managed care and value-based care saw weaker market-cap performance and multiple compression.

PwC’s outlook describes an aggregate market context. Resilient deal value alongside softer volume does not establish that every healthcare asset has access to capital or that a particular reimbursement model is durable.

I would underwrite the target’s payer concentration, contract terms, labor requirements, cash conversion and policy exposure. Separate value available through controllable operating improvements from value dependent on a favorable market multiple or an uncertain reimbursement change.

Public fact: Adonis announced on June 17 that its revenue intelligence and orchestration platform is now available in Epic Connection Hub, positioning the product directly inside provider organizations' existing operating environment. The announcement framed the problem in practical terms: margin compression, cost-to-collect pressure, workforce constraints, and growing payer complexity.

Availability in Epic Connection Hub is a distribution and integration milestone for Adonis. It does not, by itself, demonstrate local adoption, financial improvement or the amount of implementation work a provider will retain.

I would require a local baseline, a defined operational change and a financial reconciliation after fees and internal effort. The institution should retain the ability to export evidence and recover the workflow if performance or supplier conditions change.